Kragballe K, Herlin T
Arch Dermatol. 1983 Jul;119(7):548-52.
The pathophysiologic significance of increased levels of lipoxygenase compounds in psoriatic lesions was assessed in a double-blind randomized clinical study with the 5-lipoxygenase inhibitor, benoxaprofen. Forty patients with psoriasis vulgaris were treated with 600 mg of oral benoxaprofen daily or a placebo for a period of eight weeks. Benoxaprofen therapy provided excellent treatment results in about 75% of the cases. In the placebo group, only minimal improvement occurred. Most patients receiving benoxaprofen therapy reported side effects including photosensitivity, onycholysis, milia, diarrhea, and edema. In two cases, benoxaprofen was withdrawn before completion of the treatment course because of photosensitivity. Benoxaprofen may affect psoriatic epidermis either directly by the inhibition of epidermal 5-lipoxygenase or indirectly by the inhibition of the accumulation of phagocytes in psoriatic lesions. Despite serious side effects from benoxaprofen therapy, lipoxygenase-inhibiting agents deserve further study in the treatment of psoriasis.
在一项使用5-脂氧合酶抑制剂苯氧布洛芬的双盲随机临床研究中，评估了银屑病皮损中脂氧合酶化合物水平升高的病理生理意义。40例寻常型银屑病患者每天口服600 mg苯氧布洛芬或安慰剂，为期8周。苯氧布洛芬治疗在约75%的病例中提供了优异的治疗效果。在安慰剂组中，仅出现了轻微改善。大多数接受苯氧布洛芬治疗的患者报告了副作用，包括光敏反应、甲床分离、粟丘疹、腹泻和水肿。有2例患者因光敏反应在疗程结束前停用了苯氧布洛芬。苯氧布洛芬可能通过抑制表皮5-脂氧合酶直接影响银屑病表皮，或通过抑制银屑病皮损中吞噬细胞的聚集间接产生影响。尽管苯氧布洛芬治疗存在严重副作用，但脂氧合酶抑制剂在银屑病治疗中仍值得进一步研究。
